Published on 10 Jun 2016
Sylvaine Muller, creator of ImmuPharma PLC’s (LON:IMM) lead drug candidate Lupuzor, tells Proactive Investors the treatment is “unique” in its treatment for auto-immune disease lupus, as it only targets only the autoimmune system, and not the immune system.
But, she adds, “we think that we can open up the indications in which the peptide [molecule] could be effective”.
“We have already started some experiments,” Mulller says, which will target a range of diseases including inflammatory, chronic, those related to autoimmunity and those that aren’t - like asthma.
“We have first indication that are extremely promising also in these indications,” she adds.
.#ImmuPharma announces commencement of dosing in first European patients. @PanmureGordon https://t.co/CgtPQK3Dcp pic.twitter.com/8PDPrguZCW— Research Tree (@research_tree) June 8, 2016
@DirectorsTalk interview with Tim McCarthy, Chairman of #immupharma— ImmuPharma (@ImmuPharma) May 6, 2016
for full interview please click on https://t.co/7O2oGqC8Z6
Lupuzor d’ImmuPharma, l’alchimie d’un futur blockbuster : https://t.co/5f167DLUUp $IMM #lupus #lupuzor #ImmuPharma— Alerte Trading **** (@alertetrading) January 3, 2016
#Lupus treatment: #Lupuzor cleared for Phase III trials #ImmuPharma #CNRSNews https://t.co/YqsU4SxIJs pic.twitter.com/7dLfz4OkJ7— CNRS (@CNRS) December 16, 2015